Cantel Medical Corporation (CMD)
Stock Price Chart
Key Info
| Market Cap | 2.20B |
| Revenue (ttm) | 1.02B |
| Net Income (ttm) | 13.71M |
| Shares Out | 42.16M |
| EPS (ttm) | 0.32 |
| PE Ratio | 162.72 |
| Forward PE | 43.48 |
| Dividend | $0.21 |
| Dividend Yield | 0.40% |
Stock Quote
| Trading Day | Oct 23, 2020 |
| Last Price | $52.07 |
| Previous Close | $51.82 |
| Change ($) | 0.25 |
| Change (%) | 0.48% |
| Day's Open | 52.58 |
| Day's Range | 51.25 - 52.87 |
| Day's Volume | 478,022 |
| 52-Week Range | 20.81 - 79.50 |
More Stats
| Market Cap | 2.20B |
| Enterprise Value | 3.03B |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 42.16M |
| Float | 34.93M |
| EPS (basic) | 0.32 |
| EPS (diluted) | 0.32 |
| FCF / Share | 2.45 |
| Dividend | $0.21 |
| Dividend Yield | 0.40% |
| Earnings Yield | 0.61% |
| FCF Yield | 4.69% |
| Payout Ratio | 32.80% |
| Shares Short | 3.23M |
| Short Ratio | 7.14 |
| Short % of Float | 9.24% |
| Beta | 1.38 |
| PE Ratio | 162.72 |
| Forward PE | 43.48 |
| P/FCF Ratio | 21.30 |
| PS Ratio | 2.16 |
| PB Ratio | 2.99 |
| Revenue | 1.02B |
| Operating Income | 48.31M |
| Net Income | 13.71M |
| Free Cash Flow | 103.06M |
| Net Cash | -832.12M |
| Net Cash / Share | -19.74 |
| Gross Margin | 45.53% |
| Operating Margin | 4.75% |
| Profit Margin | 1.30% |
| FCF Margin | 10.14% |
| ROA | 4.02% |
| ROE | 1.97% |
| ROIC | 3.20% |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,016 | 918 | 872 | 770 | 665 | 565 | 489 | 425 | 386 | 322 |
| Revenue Growth | 10.66% | 5.3% | 13.21% | 15.86% | 17.65% | 15.6% | 14.99% | 9.97% | 20.16% | - |
| Gross Profit | 436 | 427 | 414 | 367 | 309 | 253 | 213 | 183 | 164 | 123 |
| Operating Income | 48.31 | 83.52 | 122 | 110 | 97.25 | 80.76 | 70.93 | 63.19 | 51.52 | 31.34 |
| Net Income | 13.71 | 55.04 | 91.04 | 71.38 | 59.95 | 47.95 | 43.27 | 39.24 | 31.34 | 20.43 |
| Shares Outstanding | 42.15 | 41.77 | 41.71 | 41.72 | 41.70 | 41.55 | 41.38 | 41.08 | 40.50 | 38.72 |
| Earnings Per Share | 0.32 | 1.32 | 2.18 | 1.71 | 1.44 | 1.15 | 1.04 | 0.95 | 0.77 | 0.52 |
| EPS Growth | -75.76% | -39.45% | 27.49% | 18.75% | 25.22% | 10.58% | 9.47% | 23.38% | 48.08% | - |
| Dividend Per Share | 0.11 | 0.20 | 0.17 | 0.14 | 0.12 | 0.10 | 0.09 | 0.07 | 0.06 | 0.05 |
| Dividend Growth | -47.5% | 17.65% | 21.43% | 16.67% | 20% | 11.11% | 21.62% | 19.35% | 16.98% | - |
| Operating Cash Flow | 137 | 66.93 | 126 | 108 | 80.27 | 59.07 | 64.27 | 51.49 | 50.58 | 28.20 |
| Capital Expenditures | -33.80 | -95.44 | -37.70 | -27.02 | -18.79 | -12.74 | -13.53 | -6.71 | -5.49 | -5.76 |
| Free Cash Flow | 103 | -28.51 | 88.21 | 81.18 | 61.48 | 46.34 | 50.75 | 44.78 | 45.09 | 22.44 |
| Cash & Equivalents | 278 | 44.54 | 94.10 | 36.58 | 28.37 | 31.72 | 31.78 | 34.08 | 30.19 | 18.41 |
| Total Debt | 1,110 | 231 | 197 | 126 | 116 | 78.50 | 80.50 | 95.00 | 90.00 | 24.00 |
| Net Cash / Debt | -832 | -186 | -103 | -89.42 | -87.63 | -46.78 | -48.72 | -60.92 | -59.81 | -5.59 |
| Assets | 2,072 | 1,070 | 964 | 786 | 695 | 584 | 536 | 488 | 435 | 321 |
| Liabilities | 1,342 | 409 | 355 | 262 | 240 | 177 | 171 | 167 | 159 | 87.13 |
| Book Value | 730 | 662 | 609 | 524 | 454 | 407 | 365 | 321 | 276 | 234 |
Company Profile
Company Details
| Full Name | Cantel Medical Corporation |
| Country | United States |
| Employees | 3,669 |
| CEO | George L. Fotiades |
Stock Information
| Ticker Symbol | CMD |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Unique Identifier | NYSE: CMD |
Description
Cantel Medical provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.